Boundless Bio Unveils ecDNA-Directed Cancer Therapy Strategy in New Presentation
I'm PortAI, I can summarize articles.
Boundless Bio Inc. has unveiled a new cancer therapy strategy targeting oncogene amplified cancers, focusing on extrachromosomal DNA (ecDNA). Their drug discovery platform, Spyglass, identifies synthetic lethal targets, with BBI-940, an oral Kinesin degrader, set for clinical trials in 2026. The pipeline includes four other ecDNA-selective targets, and the company has a cash runway extending into the second half of 2028 to support ongoing R&D. The full presentation is available via the provided link.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments